- Previous Close
14,090.00 - Open
14,300.00 - Bid 13,790.00 x --
- Ask 13,900.00 x --
- Day's Range
13,200.00 - 14,360.00 - 52 Week Range
9,000.00 - 19,000.00 - Volume
66,571 - Avg. Volume
109,910 - Market Cap (intraday)
84.588B - Beta (5Y Monthly) 0.72
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Anygen Co., Ltd., a bio-venture company, engages in the manufacture and sale of peptide biomaterials and drug raw materials in South Korea and internationally. It develops GMP, generic, custom, and catalog peptides, as well as offers other services. The company is also developing AGM-331 targeted for anti-cancer therapy, currently under pre-clinical development phase; AGM-130 indicated for the treatment of triple negative breast cancer, currently under Phase I development phase; AGM-380 indicated for the treatment of viral infection, currently under pre-clinical development phase; and AGM-290 indicated for the treatment of infections caused by multidrug resistant bacteria, currently under pre-clinical development phase. In addition, it is involved in the development of AGM-212 indicated for the treatment of Type 2 Diabetes, currently under pre-clinical development phase; AGM-217 indicated for the treatment of Type 2 diabetes and obesity, currently under pre-clinical development phase; and AGM-260 indicated for the treatment of Ulcerative colitis, currently under pre-clinical development phase. The company was founded in 2000 and is headquartered in Gwangju-si, South Korea.
www.anygen.comRecent News: 196300.KQ
View MorePerformance Overview: 196300.KQ
Trailing total returns as of 11/29/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 196300.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 196300.KQ
View MoreValuation Measures
Market Cap
82.79B
Enterprise Value
90.07B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
13.46
Price/Book (mrq)
10.66
Enterprise Value/Revenue
14.73
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-136.93%
Return on Assets (ttm)
-19.20%
Return on Equity (ttm)
-87.46%
Revenue (ttm)
6B
Net Income Avi to Common (ttm)
-8.22B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
357.49M
Total Debt/Equity (mrq)
81.26%
Levered Free Cash Flow (ttm)
-1.63B